(Press-News.org) Children who spend a significant amount of time on social media tend to experience a gradual decline in their ability to concentrate. This is according to a comprehensive study from Karolinska Institutet, published in Pediatrics Open Science, where researchers followed more than 8,000 children from around age 10 through age 14.
The use of screens and digital media has risen sharply in the past 15 years, coinciding with an increase in ADHD diagnoses in Sweden and elsewhere. Researchers at Karolinska Institutet in Sweden and Oregon Health & Science University in the USA have now investigated a possible link between screen habits and ADHD-related symptoms.
The study followed 8,324 children aged 9–10 in the USA for four years, with the children reporting how much time they spent on social media, watching TV/videos and playing video games, and their parents assessing their levels of attention and hyperactivity/impulsiveness.
Social media stands out
Children who spent a significant amount of time on social media platforms, such as Instagram, Snapchat, TikTok, Facebook, Twitter or Messenger, gradually developed inattention symptoms; there was no such association, however, for watching television or playing video games.
“Our study suggests that it is specifically social media that affects children’s ability to concentrate,” says Torkel Klingberg, professor of cognitive neuroscience at the Department of Neuroscience, Karolinska Institutet. “Social media entails constant distractions in the form of messages and notifications, and the mere thought of whether a message has arrived can act as a mental distraction. This affects the ability to stay focused and could explain the association.”
Significance at population level
The association was not influenced by socioeconomic background or a genetic predisposition towards ADHD. Additionally, children who already had symptoms of inattentiveness did not start to use social media more, which suggests that the association leads from use to symptoms and not vice versa.
The researchers found no increase in hyperactive/impulsive behaviour. The effect on concentration was small at the individual level. At a population level, however, it could have a significant impact.
“Greater consumption of social media might explain part of the increase we’re seeing in ADHD diagnoses, even if ADHD is also associated with hyperactivity, which didn’t increase in our study,” says Professor Klingberg.
Well-informed decisions
The researchers stress that the results do not imply that all children who use social media develop concentration difficulties, but there is reason to discuss age limits and platform design. In the study, the average time spent on social media rose from approximately 30 minutes a day for 9-year-olds to 2.5 hours for 13-year-olds, despite the fact that many platforms set their minimum age requirement at 13.
“We hope that our findings will help parents and policymakers make well-informed decisions on healthy digital consumption that support children’s cognitive development,” says the study’s first author Samson Nivins, postdoctoral researcher at the Department of Women’s and Children’s Health, Karolinska Institutet.
The researchers now plan to follow the children after the age of 14 to see if this association holds.
The study was financed by the Swedish Research Council and the Masonic Home for Children in Stockholm Foundation. There are no reported conflicts of interest.
Publication: “Digital media, Genetics and Risk for ADHD Symptoms in Children – a Longitudinal Study”, Samson Nivins, Michael A. Mooney, Joel Nigg, Torkel Klingberg, Pediatrics Open Science, online 8 December 2025, doi: 10.1542/pedsos.2025-000922.
END
Using social media may impair children’s attention
2025-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Science briefing: An update on GLP-1 drugs for obesity
2025-12-08
In a special 11 December event for science journalists, the Science Press Package team will revisit the topic recognized as Science’s Breakthrough of the year in 2023: the development of GLP-1 receptor agonists to treat obesity and their efficacy in blunting obesity-associated health problems. The Mani L. Bhaumik Breakthrough of the Year Award that the American Association for the Advancement of Science, publisher of Science, gave to researchers whose work best underpinned ...
Lower doses of immunotherapy for skin cancer give better results
2025-12-08
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.
“The results are highly interesting in oncology, as we show that a lower dose of an immunotherapy drug, in addition to causing significantly fewer side effects, actually gives better results against tumours and longer survival,” says last author Hildur Helgadottir, a researcher at the Department of Oncology-Pathology at Karolinska Institutet, who led the study.
The traditional ...
Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility
2025-12-08
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Led by Dr Max Western from the University of Bath Centre for Motivation and Behaviour Change, the study found that just 1.5% of older adults with ...
ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment
2025-12-07
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 7, 2025, AT 6:00 P.M. EST) – Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Early findings from the LIFE-L study will be presented on behalf of the multidisciplinary team by Melissa Lopez, Ph.D., RDN, at the American Society of Hematology (ASH) annual meeting in Orlando. Lopez is a postdoctoral ...
A sound defense: Noisy pupae puff away potential predators
2025-12-07
Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds.
Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when ...
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients.
“Our study met ...
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis.
Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...
New findings support a chemo-free approach for treating Ph+ ALL
2025-12-07
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.
Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group.
“The chemo-free approach ...
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
2025-12-07
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...
University of Cincinnati experts present research at annual hematology event
2025-12-06
University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6 to 9 in Orlando.
Phase 1 data testing new CLL treatment encouraging
A class of drugs called BTK inhibitors have become a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). However, the prevalence of new resistance mutations has created a need for new treatments in patients with relapsed CLL who progressed through approved standard of care options, said the Cancer Center’s Zulfa Omer, MD.
“This is an area of unmet need, with current options providing ...